Cargando…

Development of a potent small‐molecule degrader against oncogenic BRAF(V600E) protein that evades paradoxical MAPK activation

BRAF mutations are frequently observed in melanoma and hairy‐cell leukemia. Currently approved rapidly accelerated fibrosarcoma (RAF) kinase inhibitors targeting oncogenic BRAF V600 mutations have shown remarkable efficacy in the clinic, but their therapeutic benefits are occasionally hampered by ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohoka, Nobumichi, Suzuki, Masanori, Uchida, Takuya, Tsukumo, Yoshinori, Yoshida, Masayuki, Inoue, Takao, Ohki, Hitoshi, Naito, Mikihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357609/ https://www.ncbi.nlm.nih.gov/pubmed/35579105 http://dx.doi.org/10.1111/cas.15401

Ejemplares similares

Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
por: Naito, Mikihiko, et al.
Publicado: (2019)

Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line
por: Tsukumo, Yoshinori, et al.
Publicado: (2020)

Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
por: Shibata, Norihito, et al.
Publicado: (2018)

Development of protein degradation inducers of oncogenic BCR‐ABL protein by conjugation of ABL kinase inhibitors and IAP ligands
por: Shibata, Norihito, et al.
Publicado: (2017)

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib
por: Goodall, Megan L, et al.
Publicado: (2014)

Oncogenic BRAF(V600E) Induces Clastogenesis and UVB Hypersensitivity
por: Simpson, Dennis A., et al.
Publicado: (2015)

Development of Rapid and Facile Solid‐Phase Synthesis of PROTACs via a Variety of Binding Styles
por: Xu, Hanqiao, et al.
Publicado: (2022)

Preparation of the standard cell lines for reference mutations in cancer gene-panels by genome editing in HEK 293 T/17 cells
por: Suzuki, Takayoshi, et al.
Publicado: (2020)

SNIPER(TACC3) induces cytoplasmic vacuolization and sensitizes cancer cells to Bortezomib
por: Ohoka, Nobumichi, et al.
Publicado: (2017)

Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors
por: Escuin-Ordinas, Helena, et al.
Publicado: (2016)

Peptide Stapling Improves the Sustainability of a Peptide-Based Chimeric Molecule That Induces Targeted Protein Degradation
por: Yokoo, Hidetomo, et al.
Publicado: (2021)

Development of Agonist-Based PROTACs Targeting Liver X Receptor
por: Xu, Hanqiao, et al.
Publicado: (2021)

Proteasome inhibitors prevent cell death and prolong survival of mice challenged by Shiga toxin
por: Hattori, Takayuki, et al.
Publicado: (2015)

Targeted Protein Degradation by Chimeric Compounds using Hydrophobic E3 Ligands and Adamantane Moiety
por: Shoda, Takuji, et al.
Publicado: (2020)

Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function
por: Ott, Patrick A., et al.
Publicado: (2013)

Plasma proteome alterations by MAPK inhibitors in BRAF(V600)-mutated metastatic cutaneous melanoma()()
por: Babačić, Haris, et al.
Publicado: (2021)

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer
por: Pickles, Oliver J., et al.
Publicado: (2020)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma
por: Tang, Hsin-Chieh, et al.
Publicado: (2015)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Development of a Cell-penetrating Peptide that Exhibits Responsive Changes in its Secondary Structure in the Cellular Environment
por: Yamashita, Hiroko, et al.
Publicado: (2016)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Acquisition of chromosome instability is a mechanism to evade oncogene addiction
por: Salgueiro, Lorena, et al.
Publicado: (2020)

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
por: Tutuka, Candani S. A., et al.
Publicado: (2017)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Uncoupling of the LKB1-AMPKα Energy Sensor Pathway by Growth Factors and Oncogenic BRAF(V600E)
por: Esteve-Puig, Rosaura, et al.
Publicado: (2009)

Cross-Regulation between Oncogenic BRAF(V600E) Kinase and the MST1 Pathway in Papillary Thyroid Carcinoma
por: Lee, Seong Jin, et al.
Publicado: (2011)

Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene
por: Hall, Arnaldur, et al.
Publicado: (2013)

Oncogenic β-catenin mutations evade pH-regulated degradation
por: Grillo-Hill, Bree K., et al.
Publicado: (2019)

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma
por: Kumar, Raj, et al.
Publicado: (2019)

A constitutive active MAPK/ERK pathway due to BRAF(V600E) positively regulates AHR pathway in PTC
por: Occhi, Gianluca, et al.
Publicado: (2015)

SIRT6 haploinsufficiency induces BRAF(V600E) melanoma cell resistance to MAPK inhibitors via IGF signalling
por: Strub, Thomas, et al.
Publicado: (2018)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

PIK3CA(H1047R)-induced paradoxical ERK activation results in resistance to BRAF(V600E) specific inhibitors in BRAF(V600E) PIK3CA(H1047R) double mutant thyroid tumors
por: Roelli, Matthias A., et al.
Publicado: (2017)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Oncogenic Mutation BRAF V600E Changes Phenotypic Behavior of THLE-2 Liver Cells through Alteration of Gene Expression
por: Śmiech, Magdalena, et al.
Publicado: (2022)

BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay
por: Tatsuno, Michiko, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_40m7uetorul5mdtsn7ner6d2f3